progenitor cells of normal human bone marrow. Science 242:919, 1988. 
Molina JM, Scadden DT, Sakaguchi M, et al: Lack of evidence for infection of or effect on growth 
of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. 
Blood 76:2476-2482, 1990. 
Borrelli E, Heyman R, Hsi M, et al: Targeting of an inducible toxic phenotype in animal cells. Proc 
Natl Acad Sci USA 85:7572-7576, 1988. 
Heyman RA, Borrelli E, Lesley J, et al: Thymidine kinase obliteration: Creation of transgenic mice 
with controlled immune deficiency. Proc Natl Acad Sci USA 86:2698-2702, 1989. 
Moolten FL, Wells JM: Curability of tumors bearing herpes thymidine kinase genes transferred by 
retroviral vectors. JNCI 82:297, 1990. 
Lupton SD, Brunton LL, Kalkey VA, et al: Dominant positive and negative selection using a 
hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol 11:3374-3378, 1991. 
Fletcher C, Sawchuk R, Chennock B, et al: Human pharmacokinetics of the antiviral drug DHPG. 
Clin Pharmacol Ther 40:281-286, 1986. 
Rosenberg SA, Blaese MR, Anderson WF: The N2-TIL human gene transfer clinical protocol. 
Human Gene Therapy 1:73-92, 1990. 
Miller AD, Rosman GJ: Improved retroviral vectors for gene transfer and expression. BioTechniques 
7:980-990, 1989. 
Recombinant DNA Research, Volume 15 
[633] 
